Valor202020212022202320242025TTMGastos comerciales, generales y administrativos1.25 B1.2 B1.36 B1.47 B1.54 B1.67 B1.72 BInvestigación y desarrollo———————Beneficio operativo1.69 B1.8 B1.34 B1.6 B2.09 B2.04 B2.09 BTotal de ingresos no operativos16.76 M6.38 M-15.77 M-19.18 M-69.81 M-102.69 M-80.67 MGastos por intereses, netos de intereses capitalizados300.88 M282.32 M351.92 M383.13 M443.18 M539.92 M—Ingresos no operativos, una vez deducidos los gastos por intereses-300.88 M-282.32 M-351.92 M-383.13 M-443.18 M-539.92 M0Ingresos/gastos extraordinarios16.76 M6.38 M-15.77 M-19.18 M-69.81 M-102.69 M-80.67 MBeneficio antes de impuestos1.32 B1.52 B966.28 M1.18 B1.53 B1.35 B1.4 BParticipación en los beneficios26.92 M26.94 M26.52 M27.86 M26.19 M33 M35.73 MImpuestos313.93 M306.73 M198.09 M220.12 M279.66 M293.11 M305.19 MParticipación minoritaria221.03 M233.31 M221.24 M265.44 M314.39 M331.91 M340.12 MOtros ingresos/gastos después de impuestos-747 K-11.23 M-21.69 M8.94 M-13.41 M17.55 M17.98 MBeneficio neto antes de actividades interrumpidas783.29 M978.45 M546.95 M691.53 M936.34 M721.8 M781.42 MOperaciones suspendidas-9.65 M013.45 M0025 M—Beneficio neto773.64 M978.45 M560.4 M691.53 M936.34 M746.8 M781.42 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas773.64 M978.45 M560.4 M691.53 M936.34 M746.8 M781.42 MBeneficio básico por acción6.469.36.037.6211.0210.0610.94Beneficio por acción diluido6.318.95.857.4210.739.8410.71Número medio de acciones ordinarias119.8 M105.23 M92.99 M90.79 M84.99 M74.23 M—Acciones diluidas122.62 M109.95 M95.83 M93.18 M87.27 M75.89 M—EBITDA2.31 B2.47 B2.06 B2.34 B2.81 B2.75 B—EBIT1.69 B1.8 B1.34 B1.6 B2.09 B2.04 B2.09 BCosto de los ingresos———————Otros costes de producción———————Amortización y depreciación (flujo de caja)616.63 M667.75 M721.13 M736.47 M716.4 M708.25 M—
DaVita Inc. Common Stock
DaVita Inc., incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients, and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease, which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
In 2025, 68% of the company's revenues came from Medicare and other government-based health insurance programs. In 2025, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 32% of revenues in 2025, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.
The company is ranked 331st on the Fortune 500.